Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology & inflammation.

Feb 5, 2010 · As the long-standing leader in HIV, we’re committed to helping end the epidemic with the advancement of unprecedented long-acting medications for both HIV prevention and treatment.

Nov 6, 2024 · Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. Learn about our pipeline.

This site is an online medical resource that provides access to scientific information about Gilead products and related information. The information provided is not intended to be and should not be understood to provide medical advice.

21 hours ago · Key success factors for Gilead Sciences include continued innovation and successful commercialization of new products like lenacapavir, an HIV pre-exposure prophylaxis (PrEP) candidate expected to ...

Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Committed to improving the lives of patients, Gilead Medical Information strives to equip US healthcare professionals with scientific and clinical information about our products. Search our library of medical knowledge that’s available 24/7.

Search for easy-to-access information on Gilead medicines. Use the call, inquire, and chat functions to connect with a Gilead Medical representative.

For over 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed, and we’ve helped cure millions of people with hepatitis C around the world.

Jan 11, 2025 · Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.